Health committee  I'd have to go back and confirm that.

Health committee  There are couple of things here, Mr. Chair. Number one, the contracts are confidential—

Health committee  Mr. Chair, if I could finish on this, I'm very reluctant to effectively be in breach of a contract while we're in a world of competition for doses and negotiating the next round of buys. I can't speak to this email; I haven't seen it.

Health committee  I can't confirm the doubling, but I can tell you that—

Health committee  I can't answer that question, Mr. Chair, because the nature of the agreements is confidential. Remember, with the U.S. arrangement, in many of its situations, the government actually invested in the companies themselves, so you can't do a dose-per-dose comparison.

Health committee  Maybe, Mr. Chair, I can start on the procurement aspects, and I'll turn to health colleagues to talk about the duration or interval of the third dose to the extent that—

Health committee  Canada has bought more doses than we need for each Canadian, so there are those doses under contract as well as options for more. Obviously, as the science evolves, the vaccine manufacturers are working on, potentially, boosters, improved vaccines or adjusted vaccines because of

Health committee  We are in discussions with the companies around the next round of buying. I can't speak to the timelines required to get through regulatory approvals, etc., but I suspect that my Health colleagues might be able to help there.

Health committee  The supply arrangements we have in place, Mr. Chair, allow for Canada to draw from multiple sources. I'm not able to disclose at this time where the actual doses are coming from.

Health committee  We need to maintain the security of our supply.

Health committee  Mr. Chair, I'm not going to speak about the confidential nature of the contracts.

Health committee  I'm sorry, Mr. Chair. I can't elaborate more on that, at this stage.

Health committee  Again, Mr. Chair, I will not elaborate on the confidential nature of the contracts, at this stage. We are in discussions with our suppliers about taking some transparency measures related to the contracts, and that work is under way.

Health committee  The deliveries by quarter from Moderna, Pfizer and all other vaccine companies are targets. We're working with Moderna to make sure they do their best to meet the Q2 target. We are aware that Canada and some other countries are having a dip in the next delivery—

Government Operations committee  I'm going to let my colleagues correct me if my numbers are outdated, but I have between 30 and 35 contracts with indigenous companies related to the COVID response, valued somewhere around $120 million. Before we take that as official, Mr. Mills or Arianne, do you want to correc